FDA approves GSK- XenoPort postherpetic neuralgia therapy
A single 12-week principal efficacy trial and two supportive studies that met their respective primary endpoints evaluated the efficacy and safety of Horizant. A dosage of 600mg twice
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.